Talee Bio is developing a gene therapy for cystic fibrosis (CF), the first curative treatment for this disease.  Talee has developed a novel transgene and a number of innovations in a well-characterized delivery vector that collectively will overcome challenges that have previously limited the clinical viability of gene therapy for CF. Talee Bio is a collaboration among drug development professionals with more than 60 years of combined experience, and academic founders of the company, from the University of Iowa, who have been investigating CF pathogenesis and treatment, including gene therapy strategies, for more than 25 years.

Immunome uses the human immune system to discover and develop novel targets and therapies to treat cancer. New cancer-specific targets are identified by obtaining B-cells from patients who have shown an immune response against their cancer.

Tcera is discovering and developing next generation T cell therapies to treat cancer, autoimmune and infectious diseases through its T cell receptor (TCR) and T cell regulatory (Treg) programs. The TCR and Treg programs are combined with best-in-class manufacturing capability to bring novel immunotherapy products to patients.